Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03734991 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)
A Phase 3 study, sponsored by Scynexis.
- Completed
- Registry status
- Phase 3
- Development phase
- 376
- Enrollment target
NCT03734991: Completed Phase 3 study, sponsored by Scynexis.
NCT03734991 is a Phase 3 study that has completed, run by Scynexis. The registered enrollment target is 376 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (51% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03734991, a Phase 3 study, has completed, sponsored by Scynexis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 376 participants
- Enrollment target
Study Summary
This is a Phase 3, randomized, multicenter, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral Ibrexafungerp (SCY-078) compared to placebo in female subjects 12 years and older with AVVC.
Primary Outcome
measured by the percentage of subjects with clinical cure (complete resolution of signs and symptoms) at the test-of-cure (TOC) visit
Interventions
- DRUG Placebo
- DRUG Ibrexafungerp
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 376 participants |
| Start Date | 2019-01-04 |
| Est. Completion | 2019-09-04 |
| Phase | Phase 3 |
What the finished NCT03734991 record still lists
NCT03734991 is an interventional study that assigns participants to a tested intervention. The registered 376 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (51% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03734991 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03734991 about?
NCT03734991 is a clinical study titled "Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)". This is a Phase 3, randomized, multicenter, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral Ibrexafungerp (SCY-078) compared to placebo in female subjects 12 years and older with AVVC.
What is the current status of trial NCT03734991?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 376 participants. The study started on 2019-01-04. Estimated completion is 2019-09-04.
What interventions are being tested in trial NCT03734991?
The interventions under investigation include: Placebo (DRUG), Ibrexafungerp (DRUG).
Who is sponsoring clinical trial NCT03734991?
This trial is sponsored by Scynexis, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03734991's enrollment target sits among peer trials
376 988th of 2000 higher than 1,013 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03102125 · 376 participants · Phase 4
Allograft Dysfunction in Heart Transplant
- NCT05055297 · 376 participants · NA
SELUTION4BTK Trial
- NCT05912647 · 376 participants · NA
Enhancing Diabetes Management Approaches for Patients With Uncontrolled Diabetes
- NCT05963971 · 376 participants · NA
A Bilingual Virtually-based Intervention (PEDALL) for the Prevention of Weight Gain in Childhood ALL Patients Considering Key Genetic and Sociodemographic Risk Factors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI